The biotechnology company, located in the University of Valencia Science Park (PCUV), collaborates with the Institute of Biomechanics of Valencia (IBV), INCLIVA and Ascires Biomedical Group in the development of an advanced methodology for patients with obesity
The biotechnology company SABARTECH, located in the University of Valencia Science Park (PCUV), participates in a consortium with the Institute of Biomechanics of Valencia (IBV) located at the Polytechnic University of Valencia, the Institute of Health Research linked to the University Clinical Hospital of Valencia, INCLIVA and Ascires Biomedical Group in the development of an advanced methodology for patients with obesity.
The FITME project has received a total funding of 811,986.47 € from the Valencian Agency for Innovation (AVI), distributed in three annuities until 2026. This investment will allow progress in the research and development of innovative solutions for the treatment of obesity, a condition that affects a significant percentage of the population and represents a challenge for health systems.
The project aims to create a multiscale model that combines morphofunctional and omic variables to estimate in a personalized and accurate way the body composition and distribution, as well as the metabolic risk in patients with obesity
SABARTECH, specialized in genomic and microbiota analysis, participates in the FITME project (Development of an advanced methodology for comprehensive morphofunctional assessment in obese patients). This project, coordinated by the Valencia Institute of Biomechanics (IBV), aims to create a multiscale model that combines morphofunctional and omic variables to estimate in a personalized and accurate way the body composition and distribution, as well as the metabolic risk in patients with obesity.
Javier Sarasqueta and Javier Escobar, CEO and Scientific Director of SABARTECH. Photo: SABARTECH.
The proposed methodology will be objective, agile, sustainable, non-invasive and not dependent on experts, facilitating its integration into the healthcare environment. SABARTECH will provide its expertise in genomic and microbiota analysis, contributing to the development of tools that allow a comprehensive and personalized assessment of patients.
With this initiative, SABARTECH SL continues to consolidate its position as a leading company in the field of biotechnology in the field of preventomics, contributing to the development of advanced methodologies that improve the quality of life of people and strengthen the innovation ecosystem in the Valencian Community.
